arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

REGENXBIO Inc.

RGNX
$7.36 ▼ -0.38 (-4.91%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
51 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

REGENXBIO Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $388.8M
Dividend Yield —
Revenue Growth 405.7% ↗
Op. Margin 27.1%
ROIC 32.2% ↗
FCF / Share $-1.19 ↗
Trailing P/E 17.1x
Price / Book 5.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$108.02M
↑ +405.7% —
Net Income Profit after all expenses
$22.71M
↑ +125.2% —
Operating Margin Operating profit as % of sales
27.1%
↑ +114.3% 2th
FCF / Share Free cash flow per share
$-1.19
↓ -23.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
3
Cash Quality ↓
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 51 quarters